| 名稱 | PACAP (1-27), human, ovine, rat acetate |
| 描述 | PACAP (1-27), human, ovine, rat acetate (PACAP 1-27 acetate) is a novel neuropeptides originally isolated from bovine hypothalamus, also found in humans and rats. |
| 體外活性 | 通過對I-monoiodinated PACAP (1-27), human, ovine, rat進(jìn)行放射配體受體結(jié)合實(shí)驗(yàn)，確認(rèn)AR4-2J細(xì)胞表面存在PAC受體，因?yàn)镻ACAP (1-27), human, ovine, rat和PACAP(1–38)以相同的效力（Kd值為1-2 nM）置換放射配體的結(jié)合，而血管活性腸肽(VIP)的效力則低1000倍。PACAP (1-27), human, ovine, rat對VIP-氨基酸替換表現(xiàn)出明顯更高的敏感性。在AR4-2J細(xì)胞中，PACAP (1-27), human, ovine, rat展現(xiàn)出促進(jìn)IP3和cAMP生成的效能和結(jié)合親和力。 |
| 體內(nèi)活性 | 垂體腺苷酸環(huán)化酶激活多肽(PACAP (1-27), human, ovine, rat)對麻醉、通氣的豚鼠總肺阻力(RL)增加的抑制作用進(jìn)行了研究，該增加由過敏原或組胺引起。通過靜脈輸注給予PACAP (1-27), human, ovine, rat（劑量范圍0.045-4.5 nmol/kg/min）能劑量依賴性地減少吸入卵清蛋白和組胺引起的RL增加。在最高劑量時(shí)，PACAP (1-27), human, ovine, rat完全阻止了由卵清蛋白和組胺引起的RL增加。PACAP (1-27), human, ovine, rat與β2-腎上腺素受體激動(dòng)劑，沙丁胺醇（劑量范圍0.045-4.5 nmol/kg/min）的輸注同樣抑制RL增加，但沙丁胺醇比PACAP (1-27), human, ovine, rat更能增加心率[3]。 |
| 存儲條件 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 5 mM
|
| 關(guān)鍵字 | PACAP (127), human, ovine, rat acetate | PACAP 1-27 Acetate | PACAP (1 27), human, ovine, rat acetate | PACAP , human, ovine, rat Acetate |
| 相關(guān)產(chǎn)品 | PACAP 1-38 acetate | PACAP-38 (31-38), human, mouse, rat acetate | PACAP (6-38), human, ovine, rat acetate | PA-8 | PACAP (6-27) (human, chicken, mouse, ovine, porcine, rat) (trifluoroacetate salt) | PACAP-related Peptide (rat) (trifluoroacetate salt) | PACAP (1-38), human, ovine, rat | PAC1R antagonist 1 | PACAP-related Peptide (human) (trifluoroacetate salt) |
| 相關(guān)庫 | 多肽分子庫 | NO PAINS 化合物庫 |